Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trialMüge Çevik, Borisov Se, Mookho Malahleha et al.|The Lancet Infectious Diseases|2024Cited by 60
Preserved Spermatogenesis and Hormonal Function in Men Receiving a Pretomanid Regimen ( <scp>BPaMZ</scp> ) for Pulmonary Drug‐Resistant TuberculosisPauline Howell, Francesca Conradie, Antonio Lombardi et al.|Clinical Pharmacology & Therapeutics|2026Cited by 1